SN	Job Title	Closing Date and Time	Details
1	From fragmentation to federation: multi-partner OMOP implementation in Uganda enabling global real-world evidence generation	From fragmentation to federation: multi-partner OMOP implementation in Uganda enabling global real-world evidence generation	From fragmentation to federation: multi-partner OMOP implementation in Uganda enabling global real-world evidence generation
2	Guidance on the clinical management of HIV-1 persistent low-level viremia on antiretroviral treatment: a scoping review and an international Delphi consensus	Guidance on the clinical management of HIV-1 persistent low-level viremia on antiretroviral treatment: a scoping review and an international Delphi consensus	Guidance on the clinical management of HIV-1 persistent low-level viremia on antiretroviral treatment: a scoping review and an international Delphi consensus
3	Cabotegravir and Rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial	Cabotegravir and Rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial	Cabotegravir and Rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
4	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
5	“If there was no stigma around it, I would tell people”: perspectives of UK youth living with perinatally acquired HIV, their social networks and healthcare professionals on HIV status sharing	“If there was no stigma around it, I would tell people”: perspectives of UK youth living with perinatally acquired HIV, their social networks and healthcare professionals on HIV status sharing	“If there was no stigma around it, I would tell people”: perspectives of UK youth living with perinatally acquired HIV, their social networks and healthcare professionals on HIV status sharing
6	Characterization of Distinct Monocyte Subtypes and Immune Features Associated with HIV, Tuberculosis, and Coronary Artery Disease in a Ugandan Cohort Using Mass Cytometry	Characterization of Distinct Monocyte Subtypes and Immune Features Associated with HIV, Tuberculosis, and Coronary Artery Disease in a Ugandan Cohort Using Mass Cytometry	Characterization of Distinct Monocyte Subtypes and Immune Features Associated with HIV, Tuberculosis, and Coronary Artery Disease in a Ugandan Cohort Using Mass Cytometry
7	Kidney disease screening at ART initiation among adults with HIV in Uganda: A missed priority for a high-risk population	Kidney disease screening at ART initiation among adults with HIV in Uganda: A missed priority for a high-risk population	Kidney disease screening at ART initiation among adults with HIV in Uganda: A missed priority for a high-risk population
8	Impact of COVID-19 on New – onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda	Impact of COVID-19 on New – onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda	Impact of COVID-19 on New – onset Type 1 diabetes mellitus: A six-year retrospective review from two Paediatric clinics, Kampala, Uganda
9	Tetanus infection in an 11-year-old male with full infant vaccination history: a rare case report	Tetanus infection in an 11-year-old male with full infant vaccination history: a rare case report	Tetanus infection in an 11-year-old male with full infant vaccination history: a rare case report
10	Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda	Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda	Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda
11	Body Composition Changes in Children Living with HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial	Body Composition Changes in Children Living with HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial	Body Composition Changes in Children Living with HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
12	Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption	Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption	Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption
13	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ Rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ Rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ Rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.
14	The process of developing an HIV disclosure intervention for youth with perinatally acquired HIV: The HIV Empowering Adults’ Decisions to Share – UK/Uganda Project (Heads-Up)	The process of developing an HIV disclosure intervention for youth with perinatally acquired HIV: The HIV Empowering Adults’ Decisions to Share – UK/Uganda Project (Heads-Up)	The process of developing an HIV disclosure intervention for youth with perinatally acquired HIV: The HIV Empowering Adults’ Decisions to Share – UK/Uganda Project (Heads-Up)
15	Tuberculosis research principles and priorities in children and adolescents: an international consensus statement	Tuberculosis research principles and priorities in children and adolescents: an international consensus statement	Tuberculosis research principles and priorities in children and adolescents: an international consensus statement
16	Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial	Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial	Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
17	Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial	Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial	Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial
18	Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial	Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial	Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial
19	Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios	Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios	Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios
20	Clients’ Perspectives on Switching from Old Stable ART Regimens to New Dolutegravir-based Regimen at Joint Clinical Research Centre Uganda	Clients’ Perspectives on Switching from Old Stable ART Regimens to New Dolutegravir-based Regimen at Joint Clinical Research Centre Uganda	Clients’ Perspectives on Switching from Old Stable ART Regimens to New Dolutegravir-based Regimen at Joint Clinical Research Centre Uganda
21	Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children.	Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children.	Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children.
22	The imperative for increased investment for an HIV cure	The imperative for increased investment for an HIV cure	The imperative for increased investment for an HIV cure
23	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
24	The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV	The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV	The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV
25	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
26	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
27	BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa	BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa	BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
28	Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial	Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial	Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial
29	Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial	Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial	Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
30	Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV	Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV	Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV